Diazepam & Gabapentin Interaction

Diazepam (Valium) and gabapentin (Neurontin) both depress the central nervous system, and their combination can cause dangerous levels of sedation, respiratory depression, and, in severe cases, fatal overdose. The FDA added a boxed warning to gabapentinoids in 2019 regarding the risk of respiratory depression when combined with CNS depressants.

This combination is frequently encountered because diazepam is prescribed for anxiety, seizures, and muscle spasms, while gabapentin is used for neuropathic pain, seizures, and increasingly for anxiety. Patients with chronic pain and anxiety may be prescribed both, sometimes by different providers.

The opioid crisis led to increased gabapentin prescribing as a perceived safer alternative to opioids for pain, but combining gabapentinoids with benzodiazepines introduces its own serious risks.

Diazepam enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors, producing sedation, anxiolysis, muscle relaxation, and anticonvulsant effects. It also causes respiratory depression by reducing brainstem sensitivity to carbon dioxide.

Gabapentin, despite its name, does not directly bind GABA receptors. It binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. However, the net CNS depressant effect is additive with benzodiazepines. The combination impairs both cortical function (producing deeper sedation) and brainstem respiratory drive (increasing apnea risk), particularly during sleep.

The FDA's 2019 safety communication reported that gabapentinoids were involved in a growing number of respiratory depression cases, particularly when combined with CNS depressants like benzodiazepines and opioids. Elderly patients, those with respiratory conditions (COPD, sleep apnea), and patients also taking opioids are at highest risk.

Beyond respiratory depression, the combination impairs cognitive function, coordination, and reaction time, significantly increasing fall risk in older adults and driving impairment in all ages. Accidental overdose deaths involving gabapentin and benzodiazepines have been increasingly reported to poison control centers.

If both medications are necessary, use the lowest effective doses of each. Start low and titrate slowly, especially in elderly patients or those with respiratory compromise. Take gabapentin at bedtime if once-daily dosing is appropriate, as peak sedation coincides with sleep.

Avoid alcohol completely while on both medications. Do not add opioids to this combination unless absolutely necessary with close monitoring. Patients should not drive or operate machinery until they understand how the combination affects them.

Monitor respiratory rate, oxygen saturation, and level of consciousness during initiation and dose adjustments. In patients with sleep apnea or COPD, consider overnight pulse oximetry to detect nocturnal respiratory depression.

Assess cognitive function and fall risk at each visit. In elderly patients, use a validated fall risk assessment tool. Monitor for signs of excessive CNS depression: slurred speech, extreme drowsiness, confusion, difficulty waking, slow or shallow breathing.

For anxiety in patients on gabapentin, buspirone is a non-sedating anxiolytic without CNS depressant effects. SSRIs or SNRIs treat anxiety disorders without additive respiratory depression. Hydroxyzine provides mild anxiolysis with less respiratory risk than benzodiazepines.

For neuropathic pain in patients on diazepam, duloxetine and amitriptyline are effective for nerve pain without the gabapentinoid respiratory risk. Topical lidocaine or capsaicin provide localized relief without systemic CNS depression.